Transformingthe treatment of chronic disease.
Enhancingthe body’s healing response.
Rebalancingthe immune system.
Discoveringthe power of VSELs.
Leveragingexperience in cell therapy.
AMR-001: NeoStem's Product Candidate for AMI
Advances in regenerative medicine hold the promise to preserve heart muscle function after a severe heart attack. Watch to learn more about AMR-001 and Amorcyte, a NeoStem subsidiary.
News + Events
NeoStem’s Subsidiary, Progenitor Cell Therapy LLC (“PCT”), Expands Manufacturing Relationship with ImmunoCellular Therapeutics for Dendritic Cell Vaccines
Dec 3, 2013 — Learn More
NeoStem Announces Third Quarter 2013 Financial Results and Provides Corporate Update - Company now has cash reserves in excess of $50 million
Nov. 7, 2013 — Learn More
We believe the financing environment for emerging biopharmaceutical companies such as NeoStem has been very favorable – the general interest among investors is stronger than it has been for more than five years – making it a prudent time to capitalize on this opportunity in the marketplace to raise additional funds. With our proprietary cell therapy products all in the development stage, additional funding for these programs is essential. In addition to strengthening our balance sheet, this recent equity financing has allowed us to diversify our shareholder base and to add new high quality institutional investors to our holders. We believe it will also have the effect of improving the liquidity of our shares in the market.
August 30, 2013